Quest Diagnostics has been riding a strong wave of positive momentum, with its stock rally of 25.6% in a year and a leap of 27.3% in its value, it's clear to see investors are identifying the potential in DGX. Mixed signals from analysts showcase some apprehension regarding the company's near-term outlook, however, they don't overlook the strong fundamentals in place. Recent
acquisitions include
Fresenius Medical Care clinical testing assets which will extend the company's reach to serve additional 200,000 dialysis patients annually. Q2 2025 earnings show substantial revenue growth and subsequently an increase in their quarterly cash dividend. The company's CEO will be attending the
Baird Healthcare Conference where innovative strategies are expected to be shared. Their collaboration with
Google Cloud for AI healthcare data analysis further emphasizes the company's commitment to data-driven healthcare innovation. Quest has launched a revolutionary
FDA-cleared blood test to detect early Alzheimer's with a remarkable 97% accuracy. Despite certain bearish technicalities and weak signals amid volatility, the long-term picture for growth remains intact. Towards a more sustainable future, Quest announced the development of a
multi-cancer stratification blood test based on MD Anderson Technology.
Quest Diagnostics DGX News Analytics from Tue, 03 Dec 2024 08:00:00 GMT to Sat, 16 Aug 2025 13:17:25 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -4
